Skip to main content

Are lung nodules common after Bendeka & Rituxan therapy?

Medically reviewed by Carmen Pope, BPharm. Last updated on May 5, 2025.

Official Answer by Drugs.com

Although there have been a few case reports of interstitial lung disease (ILD) developing following Rituximab (RTX) therapy, it is considered a rare complication of rituximab therapy but one that doctors should monitor for because it may be potentially fatal.

Published case reports mostly reported ILD happening in people taking Rituximab; however, at least two reported the combination of rituximab and bendamustine (Bendeka), for example:

Interstitial Lung Disease (ILD) is an umbrella term for a large group of lung diseases that cause scarring (fibrosis) of the lungs. Scarring makes it difficult to breathe and get oxygen to the bloodstream.

What is a lung nodule?

A lung nodule is a small round or oval solid overgrowth of tissue in the lungs that is seen on an X-ray or computed tomography (CT) scan.

Nodules are common and they show up on about one in every 500 chest x-rays. There may be just one solitary nodule or there may be several. Lung nodules may be benign (noncancerous) or cancerous. Nodules are more likely to be benign if:

References

Read next

How soon can you start chemo after port placement?

Chemotherapy can typically begin within a few days to 2 weeks after port placement, depending on factors like healing progress and treatment urgency. While same-day chemotherapy is possible in some cases, most healthcare providers recommend a short waiting period to ensure proper recovery and port functionality.

Continue reading

What is the difference between Truxima and Rituxan?

Truxima (rituximab-abbs) is a biosimilar to Rituxan (rituximab). While both drugs are CD20-directed cytolytic antibodies used to treat non-Hodgkin’s lymphoma (NHL), Rituxan has additional FDA-approved indications beyond NHL. Continue reading

What is the success rate of Rituxan (rituximab) in patients with blood cancers?

In patients with hematological or blood cancers, including non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), Rituxan’s success is measured in a number of ways. It is measured by looking at how long patients responded to treatment (median duration of response), how long they live without their disease progressing (progression-free survival) and how many patients respond to treatment (response rate).

Rituxan treatment improves outcomes in certain patients with NHL. Adding Rituxan alongside standard therapies enhances the response patients have to treatment and improves overall outcomes, including increasing the time patients live for without experiencing a progression of their disease.

Rituxan helps to improve overall survival in certain patients with CLL and also helps to increase the time patients live for without experiencing disease progression. Adding Rituxan alongside standard therapy enhances the response patients have to therapy. Continue reading

See also:

Related medical questions

Drug information

Related support groups